https://www.optimumcomms.com/wp-content/uploads/2026/09/Currus-website-logo.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-10-27 08:31:402026-10-27 08:31:40Octane Biotech and Currus Biologics Automate Manufacturing of CUR-001 CAR T-Cell Therapy on the Cocoon® Platform
https://www.optimumcomms.com/wp-content/uploads/2026/09/Currus-website-logo.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-10-27 08:31:402026-10-27 08:31:40Octane Biotech and Currus Biologics Automate Manufacturing of CUR-001 CAR T-Cell Therapy on the Cocoon® Platform
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-10-23 18:32:522026-10-23 18:32:52Hansa Biopharma announces positive Idefirix PAES results presented in the High-Impact Clinical Trials session at ASN Kidney Week
https://www.optimumcomms.com/wp-content/uploads/2023/02/Neuraxpharm_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-10-23 10:23:382026-10-23 10:23:38New long-term and real-world data on BRIUMVI® (ublituximab) presented at the 10th Joint ACTRIMS-ECTRIMS Meeting 2026
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-10-21 09:09:392026-10-21 09:09:39Hansa Biopharma announces Idefirix PAES late-breaking abstract selected for oral presentation in High-Impact Clinical Trials session at ASN Kidney Week
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-10-20 16:57:172026-10-20 16:57:40Hansa Biopharma announces submission of IND Application to US FDA for HNSA-5487 in GBS
https://www.optimumcomms.com/wp-content/uploads/2026/10/GESYNTA.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-10-20 14:31:222026-10-20 14:31:22Gesynta Pharma completes enrollment in Phase 2 NOVA trial evaluating vipoglanstat in endometriosis
https://www.optimumcomms.com/wp-content/uploads/2026/06/Mestag_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-10-20 14:05:492026-10-20 14:05:49Mestag Therapeutics Appoints Philip Astley-Sparke and Victor Sandor, M.D.C.M., to its Board of Directors
https://www.optimumcomms.com/wp-content/uploads/2026/03/Template_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-10-15 12:01:032026-10-15 12:01:03R1 Therapeutics to present Phase 2b trial-in-progress poster for AP306 at ASN Kidney Week 2026
https://www.optimumcomms.com/wp-content/uploads/2026/10/ionctura-website-logo.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-10-15 08:38:022026-10-15 08:38:32iOnctura appoints Paul Sekhri as Chair of its Board of Directors
https://www.optimumcomms.com/wp-content/uploads/2026/07/Mission_Therapeutics_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-10-15 08:32:102026-10-16 09:53:35Mission Therapeutics doses first Parkinson’s patient in Phase 1b study of potential disease-modifying treatment MTX325
https://www.optimumcomms.com/wp-content/uploads/2025/09/DaltonTx.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-10-15 08:30:562026-10-15 08:31:05DaltonTx awarded grant to accelerate AI-powered tuberculosis drug discovery
https://www.optimumcomms.com/wp-content/uploads/2026/10/Template_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-10-14 08:36:592026-10-14 08:36:59Sapreme Therapeutics announces oral presentation of new preclinical data on lead Duchenne muscular dystrophy candidate SPM-2551 at OTS 2026
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-10-13 11:32:372026-10-13 11:32:37Hansa Biopharma to participate in Virtual US Bancorp / BTIG Kidney Health Forum
https://www.optimumcomms.com/wp-content/uploads/2026/10/ionctura-website-logo.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-10-09 10:32:492026-10-09 11:06:47A promising new chapter for PI3Kδ inhibition: Nature Communications publications reveal novel mechanism behind iOnctura’s roginolisib
https://www.optimumcomms.com/wp-content/uploads/2026/06/BioEurope_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-10-07 08:41:262026-10-07 10:44:02BIO-Europe C-Suite Survey: Biopharma dealmaking set to accelerate, but investor caution still caps ambition
https://www.optimumcomms.com/wp-content/uploads/2024/05/Template_Logo_300x180px-80x80Web_Logos-1.jpg
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-10-06 08:43:502026-10-06 08:43:50Resolution Therapeutics to present interim Phase I/II EMERALD study data on RTX001 as a late-breaker at AASLD 2026We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
